Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-30T04:08:00.155Z Has data issue: false hasContentIssue false

An interferon-α-induced psychotic disorder in a patient with chronic hepatitis C

Published online by Cambridge University Press:  16 April 2020

P. Petrikis
Affiliation:
‘A’ Psychiatric Clinic of Aristotle University of Thessaloniki, Psychiatric Hospital of Thessaloniki, 36 Konstantinoupoleos St., Thessaloniki56429, Greece
A. Balla
Affiliation:
‘A’ Psychiatric Clinic of Aristotle University of Thessaloniki, Psychiatric Hospital of Thessaloniki, 36 Konstantinoupoleos St., Thessaloniki56429, Greece
A. Karavatos
Affiliation:
‘A’ Psychiatric Clinic of Aristotle University of Thessaloniki, Psychiatric Hospital of Thessaloniki, 36 Konstantinoupoleos St., Thessaloniki56429, Greece
Get access

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Case report
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cabrera Gomez, JA, Cordero Gutierrez, JR, Fernandez Lopez, O, Reyes Gutierrez, B, Romero Garcia, K, Simon Conuegra, Jet al. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1993; 7: 2737.CrossRefGoogle ScholarPubMed
Danzer, R, Wollman, E, Vitkovic, L, Yirmiya, R.Cytokines and depression: fortuitous or causative association?. Mol Psychiatry 1999; 4: 328332.CrossRefGoogle Scholar
Hadden, JW.Immunopharmacology of cancer, infection and autoimmunity. Fundam Clin Pharmacol 1987; 4: 283296.CrossRefGoogle Scholar
Katila, H, Cantell, C, Appelberg, B, Wahlbeck, K, Naukkarinen, H, Rimon, R.Interferon-alpha as adjuvant treatment in chronic schizophrenia. Neuropsychobiology 1993; 28: 192196.CrossRefGoogle ScholarPubMed
Lemonnier, E, Condat, B, Paillere-Martinot, ML, Chollet, R, Allilaire, JF.Syndrome de perseceution sous interferon: à propose d'un cas. Ann Med Psychol 1996; 154: 246248.Google Scholar
Lerner, DM, Stoudemire, A, Rosenstein, DL.Neuropsychiatric toxocity associated with cytokine therapies. Psychosomatics 1999; 40: 428435.CrossRefGoogle Scholar
Licinio, L, Kling, MA, Hauser, P.Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998; 25 (Suppl 1): 3038.Google ScholarPubMed
Monji, A, Yoshida, I, Tashiro, KI, Hayashi, Y, Tashiro, N.A case of persistent manic depressive illness induced by interferon-alpha in the treatment of chronic hepatitis C. Psychosomatics 1998; 39: 562564.CrossRefGoogle ScholarPubMed
Okada, F.Interferon-induced depression: just one of Bonhoefer’s exogene reactiontypen or a clue to understanding psychoimmunological aspects of depression?. J Mol M 1995; 73: 99100.CrossRefGoogle ScholarPubMed
Shiffman, ML.The use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl 1): 2534.Google ScholarPubMed
Vial, T, Choquet-Kastylevsky, G, Liautard, C, Descotes, J.Endocrine and neurological adverse effects of therapeutic interferons. Toxicology 2000; 142: 161172.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.